Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study (vol 41, pg 3523, 2023)

被引：0
|
作者：
Cartron
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 25期
关键词：
D O I：
10.1200/JCO.23.01377
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4187 / 4187
页数：1
相关论文
共 50 条
  • [1] Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study
    Cartron, Guillaume
    Bachy, Emmanuel
    Tilly, Herve
    Daguindau, Nicolas
    Pica, Gian-Matteo
    Bijou, Fontanet
    Mounier, Christiane
    Clavert, Aline
    Damaj, Gandhi Laurent
    Slama, Borhane
    Casasnovas, Olivier
    Houot, Roch
    Bouabdallah, Krimo
    Sibon, David
    Fitoussi, Olivier
    Morineau, Nadine
    Herbaux, Charles
    Gastinne, Thomas
    Fornecker, Luc-Matthieu
    Haioun, Corinne
    Launay, Vincent
    Araujo, Carla
    Benbrahim, Omar
    Sanhes, Laurence
    Gressin, Remy
    Gonzalez, Hugo
    Morschhauser, Franck
    Ternant, David
    Xerri, Luc
    Tarte, Karin
    Pranger, Delphine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (19) : 3523 - +
  • [2] Subcutaneous rituximab induction followed by short rituximab maintenance to improve progression-free survival in patients with low-tumor burden follicular lymphoma: Final results of FLIRT phase III trial, a LYSA study.
    Cartron, Guillaume
    Bachy, Emmanuel
    Tilly, Herve
    Daguindau, Nicolas
    Pica, Gian Matteo
    Bijou, Fontanet
    Mounier, Christiane
    Clavert, Aline
    Damaj, Gandhi Laurent
    Slama, Borhane
    Casasnovas, Olivier
    Houot, Roch
    Bouabdallah, Krimo
    Sibon, David
    Fitoussi, Olivier
    Morineau, Nadine
    Morschhauser, Franck
    Xerri, Luc
    Tarte, Karin
    Pranger, Delphine
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Combination of Ibrutinib with Rituximab Versus Placebo with Rituximab for First-Line Treatment of Follicular Lymphoma: PERSPECTIVE, a Randomized Phase 3 Study
    Flinn, Ian
    Gordon, Leo
    Rule, Simon
    Chen, Robert
    Kwei, Long
    Chu, Alvina D.
    Fowler, Nathan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S277 - S278
  • [4] Subcutaneous Rituximab and Chemotherapy Achieves Similar Overall Response Rates to Intravenous Rituximab in First-Line Follicular Lymphoma: Efficacy and Safety Results of the Phase III SABRINA Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (08) : 6 - 7
  • [5] SUBCUTANEOUS RITUXIMAB AND CHEMOTHERAPY ACHIEVES SIMILAR OVERALL RESPONSE RATES TO INTRAVENOUS RITUXIMAB IN FIRST-LINE FOLLICULAR LYMPHOMA: EFFICACY AND SAFETY RESULTS OF THE PHASE III SABRINA STUDY
    Davies, A.
    Merli, F.
    Mihaljevic, B.
    Mercadal, S.
    Solal-Celigny, P.
    Boehnke, A.
    Berge, C.
    Cambon, N.
    Macgregor, L.
    Brewster, M.
    Barrett, M.
    MacDonald, D.
    HAEMATOLOGICA, 2014, 99 : 225 - 225
  • [6] Rituximab as first-line treatment of patients with follicular lymphoma (FL) and a low-burden tumor: Clinical and molecular evaluation.
    Solal-Celigny, P
    Salles, G
    Brousse, N
    Eftekhari, P
    Soubeyran, P
    Lacotte, L
    Deconinck, E
    Haioun, C
    Foussard, C
    Sebban, C
    Stamatoulas, A
    Milpied, N
    Boue, F
    Taillan, B
    Lederlin, P
    Najman, A
    Mathieu-Boue, A
    Benzohra, A
    Colombat, P
    BLOOD, 1999, 94 (10) : 631A - 631A
  • [7] Phase III study of watchful waiting vs. rituximab as first-line treatment in advanced stage follicular lymphoma with low tumour burden (JCOG1411, FLORA study)
    Miyamoto, Kenichi
    Fukuhara, Noriko
    Maruyama, Dai
    Shibata, Taro
    Nakamura, Kenichi
    Ishizawa, Kenichi
    Tsukasaki, Kunihiro
    Nagai, Hirokazu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (08) : 777 - 780
  • [8] Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
    Davies, Andrew
    Merli, Francesco
    Mihaljevic, Biljana
    Mercadal, Santiago
    Siritanaratkul, Noppadol
    Solal-Celigny, Philippe
    Boehnke, Axel
    Berge, Claude
    Genevray, Magali
    Zharkov, Artem
    Dixon, Mark
    Brewster, Michael
    Barrett, Martin
    MacDonald, David
    LANCET HAEMATOLOGY, 2017, 4 (06): : E272 - E282
  • [9] Subcutaneous Epcoritamab in Combination with Rituximab plus Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial
    Falchi, Lorenzo
    Leslie, Lori A.
    Belada, David
    Kopeckova, Katerina
    Offner, Fritz
    Brody, Joshua
    Canales, Miguel
    Martin Garcia-Sancho, Alejandro
    Nijland, Marcel
    Andersson, P-O
    Awan, Farrukh T.
    Christensen, Jacob Haaber
    Drott, Kristina
    Hellstrom, Mats
    Lewerin, Catharina
    Narkhede, Mayur
    Snauwaert, Sylvia
    Wahlin, Bjorn E.
    Rana, Ali
    Abbas, Aqeel
    Wang, Liwei
    Minh Dinh
    Vermaat, Joost S. P.
    Abrisqueta, Pau
    BLOOD, 2022, 140 : 1471 - 1473
  • [10] Subcutaneous (SC) Mosunetuzumab (mosun) As First-Line Therapy for Patients (pts) with High Tumor-Burden Follicular Lymphoma (FL): First Results of a Multicenter Phase 2 Study
    Falchi, Lorenzo
    Okwali, Michelle
    Ghione, Paola
    Owens, Colette
    Hamlin, Paul A.
    Lue, Jennifer Kimberly
    Epstein-Peterson, Zachary D.
    Palomba, Maria Lia
    Kumar, Anita
    Torka, Pallawi
    Leslie, Lori A.
    Lopes, Alexandra Ferreira
    Martinova, Anastasia
    Wood, Lauren
    Grieve, Clare
    Amador, Walter Ramos
    Vardhana, Santosha A.
    Zelenetz, Andrew D.
    Salles, Gilles
    BLOOD, 2023, 142
12345